Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Comparison of TCP-25 formulation in HPC with the related polymer HEC.
  • Fig. S2. Dose-response studies of TCP-25 gel formulations.
  • Fig. S3. Antimicrobial activity of TCP-25 HEC formulation against clinical isolates and reference strains.
  • Fig. S4. In vivo antibacterial effects of TCP-25 HEC gel in a mouse model of subcutaneous infection.
  • Fig. S5. In vivo antibacterial effects of TCP-25 HEC gel in a mouse model of prevention of infection.
  • Fig. S6. In vitro activity of TCP-25 against P. aeruginosa isolated from minipig wounds with secondary infection.
  • Fig. S7. Effects of TCP-25 gel in a porcine partial thickness wound model of superinfection.
  • Fig. S8. In vitro release and in vivo pharmacokinetics of TCP-25 gel.
  • Fig. S9. Partial thickness wound on minipig skin.
  • Fig. S10. Rheological properties of TCP-25 gel.
  • Fig. S11. Stability, activity, and release profile of the TCP-25 HEC formulation.
  • Fig. S12. Stability of TCP-25 in human, minipig, and mouse plasma.
  • Fig. S13. Activity of the silver-containing dressing Mepilex Ag against S. aureus.
  • Fig. S14. Cytokine analysis of wound fluid collected on days 2 and 3.
  • Fig. S15. IL-1β analysis of the wound fluid collected on days 2, 3, and 5 from the animal model of established infection.
  • Fig. S16. Single-dose toxicity study in mice.
  • Fig. S17. Schematic figure illustrating the dual function of TCP-25 gel in the wound environment.
  • Table S1. MIC values for TCP-25 against clinical isolates and reference strains.
  • Table S2. MIC values of TCP-25 against multidrug-resistant bacteria.
  • Table S3. Clinical scoring of minipig wounds.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual subject-level data.